Reuters logo
BRIEF-Resverlogix announces second positive recommendation for Apabetalone (RVX-208) Phase 3 study
December 5, 2016 / 5:36 PM / 9 months ago

BRIEF-Resverlogix announces second positive recommendation for Apabetalone (RVX-208) Phase 3 study

Dec 5 (Reuters) - Resverlogix Corp :

* Press release - Resverlogix announces second positive recommendation from Data Safety Monitoring Board for Phase 3 study of Apabetalone (RVX-208)

* Data and Safety Monitoring Board reviewed available study data and noted that no safety or efficacy concerns were identified

* “First patients in trial have now surpassed one year mark and Apabetalone remains well-tolerated with a consistent safety profile.”

* Data and Safety Monitoring Board for Co’s Phase 3 BETonMACE trial recommended that study to continue as planned without any modifications Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below